RTP Mobile Logo
COVID-19 and Oncology Care: Discussing the Impact of the Pandemic on the Management of Lung, Breast, Gastrointestinal and Genitourinary Cancers (Audio Program)
Released August 2020

Featuring perspectives from Drs Tanios Bekaii-Saab, Stephen V Liu, William K Oh, and Tiffany A Traina. (Audio Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This educational activity has been designed to meet the educational needs of medical oncologists, hematology-oncology fellows and other allied cancer professionals.

    LEARNING OBJECTIVES

    • Evaluate the best-practice approaches of disease-specific experts to help minimize the risk of coronavirus infection in both inpatient and outpatient cancer treatment settings.
    • Individualize the selection of systemic therapy for patients with early and advanced cancers to account for the realities of the COVID-19 pandemic and help reduce the potential for SARS-CoV-2 exposure.
    • Consider the rationale for and appropriateness of adapting specific cancer management and follow-up practices to limit in-person interaction in light of the current need for social distancing.
    • Appraise expert perspectives and real-world experiences when implementing a plan of care for patients with various cancers who are diagnosed with COVID-19.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Audio Program: Research To Practice designates this enduring material for a maximum of 4.75 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Video Program: Research To Practice designates this enduring material for a maximum of 4 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of these CME activities, which includes participation in the evaluation components, enables the participant to earn up to 4.75 (audio) and 4 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/COVID19/POC/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/COVID19/POC/Video.

    Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/COVID19/POC/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/COVID19/POC.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Tanios Bekaii-Saab, MD
    Professor, Mayo Clinic College of Medicine and Science
    Program Leader, Gastrointestinal Cancer, Mayo Clinic Cancer Center
    Consultant, Mayo Clinic in Arizona
    Phoenix, Arizona

    Advisory Committee: Immuneering Corporation, Imugene, Sun BioPharma Inc; Consulting Agreements: Array BioPharma Inc, a subsidiary of Pfizer Inc, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Celularity, Daiichi Sankyo Inc, Eisai Inc, Exact Sciences, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Natera Inc, Seattle Genetics, Sobi, Treos Bio; Contracted Research: AbGenomics, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, Bayer HealthCare Pharmaceuticals, Boston Biomedical Inc, Bristol-Myers Squibb Company, Clovis Oncology, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Merus BV, Mirati Therapeutics, Novartis, Seattle Genetics; Data and Safety Monitoring Board/Committee: 1Globe Health Institute, AstraZeneca Pharmaceuticals LP, Exelixis Inc, Lilly, Merck, Pancreatic Cancer Action Network.

    Stephen V Liu, MD, PhD
    Associate Professor of Medicine
    Georgetown University Hospital
    Washington, DC

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, G1 Therapeutics, Genentech, a member of the Roche Group, Guardant Health, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, PharmaMar, Regeneron Pharmaceuticals Inc, Takeda Oncology; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Merck, Merck Sharp & Dohme Corp, Pfizer Inc, Takeda Oncology; Contracted Research: Alkermes, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Bristol-Myers Squibb Company, Corvus Pharmaceuticals, Genentech, a member of the Roche Group, Lilly, Lycera, Merck, Merus BV, Molecular Partners, Pfizer Inc, Rain Therapeutics, RAPT Therapeutics, Spectrum Pharmaceuticals Inc, Turning Point Therapeutics; Data and Safety Monitoring Board/Committee: Taiho Oncology Inc.

    William K Oh, MD
    Chief, Division of Hematology and Medical Oncology
    Professor of Medicine and Urology
    Ezra M Greenspan, MD Professor in Clinical Cancer Therapeutics
    Icahn School of Medicine at Mount Sinai
    Associate Director of Clinical Research
    The Tisch Cancer Institute
    Mount Sinai Health System
    New York, New York

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, CPS Companion Diagnostics, Janssen Biotech Inc, Sanofi Genzyme, Sema4, TeneoBio.

    Tiffany A Traina, MD
    Vice Chair, Department of Medicine
    Associate Attending Physician
    Section Head, Triple-Negative Breast Cancer Clinical Research Program
    Memorial Sloan Kettering Cancer Center
    Associate Professor of Medicine
    Weill Cornell Medicine
    New York, New York

    Consulting Agreements: Aduro Biotech, Advaxis Inc, AstraZeneca Pharmaceuticals LP, Athenex Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Genomic Health Inc, Halozyme Inc, Innocrin Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, Merck, Pfizer Inc, Puma Biotechnology Inc, Samsung Bioepis, Seattle Genetics; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Carrick Therapeutics, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Immunomedics Inc, Innocrin Pharmaceuticals Inc, Novartis, Pfizer Inc; Speakers Bureau: Genentech, a member of the Roche Group.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Daiichi Sankyo Inc.

    Release date: August 2020
    Expiration date: August 2021

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Listen to audio:
Select publications